financetom
Business
financetom
/
Business
/
Planet Labs Stock Gains Ahead Of Q4 Earnings: What Investors Need To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Planet Labs Stock Gains Ahead Of Q4 Earnings: What Investors Need To Know
Mar 19, 2026 7:45 AM

Planet Labs PBC ( PL ) stock is edging up Thursday morning as investors weigh two recent business updates that point to rising demand for the company's satellite data and AI services, while also looking ahead to its fourth-quarter earnings report after the closing bell.

Planet is expected to report a fourth-quarter loss of $0.08 per share on revenue of $78.18 million. Here’s what investors need to know.

Planet Labs stock is trending lower. Why is PL stock retreating?

Planet Labs Partners With Nvidia to Boost AI-Powered Satellite Imaging

One recent catalyst is Planet's newly announced collaboration with Nvidia to build a GPU-native AI engine for planetary intelligence. The partnership is designed to accelerate the processing of satellite imagery, helping Planet turn raw data into actionable insights much faster than traditional CPU-based systems.

Planet said the effort will use Nvidia technologies, including Blackwell, IGX Thor and the CorrDiff generative AI model, to sharpen image resolution and support the creation of a searchable, multi-dimensional map of Earth that can detect patterns and anomalies in near real time.

Planet Labs Lands Defense Role in $151 Billion SHIELD Contract

Another tailwind came from Planet's selection as a prime contractor under the Missile Defense Agency's SHIELD indefinite-delivery, indefinite-quantity contract, which has a ceiling value of $151 billion.

Through that program, Planet said it will provide global monitoring, maritime domain awareness, AI-powered detections, warnings and analytics for defense and intelligence customers.

Planet Labs RSI Shows Mostly Neutral Momentum

Planet Labs' RSI has mostly fluctuated in the neutral range over the past year, with several spikes into overbought territory above 70.

It has rarely dipped into oversold levels below 30, suggesting the stock has generally maintained moderate momentum rather than extreme weakness.

PL Shares Trade Flat Thursday

PL Price Action: Planet Labs shares were up 2.62% at $25.46 at the time of publication on Thursday, according to Benzinga Pro data.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard seeks probe after former Pfizer execs pull support for its campaign
Oct 10, 2024
(Reuters) - Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday. Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, who were reportedly helping the activist investor in its plan to push...
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Oct 10, 2024
Indivior PLC ( INDV ) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior ( INDV ) trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion –...
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Oct 10, 2024
09:25 AM EDT, 10/10/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday that volixibat has received breakthrough therapy designation from the US Food and Drug Administration as a potential treatment for cholestatic pruritus related to primary biliary cholangitis. The company said the designation is based on the interim analysis of a phase 2b study that demonstrated statistically significant...
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Oct 10, 2024
09:24 AM EDT, 10/10/2024 (MT Newswires) -- Delta Air Lines ( DAL ) issued a weak fourth-quarter earnings outlook amid expectations for subdued travel demand around the US Presidential elections in November, as the air carrier's bottom line fell short of market estimates in the prior three-month period while revenue beat Wall Street forecasts. The airline anticipates adjusted earnings to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved